Trofosfamide
Chemical compound
- L01AA07 (WHO)
- N,N,3-tris(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amide 2-oxide
- 22089-22-1
Y
- 65702
- 59129
N
- H64JRU6GJ0
- D07252
Y
- ChEMBL462019
N
- DTXSID60865031
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl
InChI
- InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2
N
- Key:UMKFEPPTGMDVMI-UHFFFAOYSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Trofosfamide (INN) is a nitrogen mustard alkylating agent. It is sometimes abbreviated "TRO".[1] It has been used in trials to study its effects on ependymoma, medulloblastoma, sarcoma, soft tissue,[clarification needed] supratentorial PNET, and recurrent brain tumors.[2]
References
- v
- t
- e
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e